Secondly, LGMN knockdown TAMs were shown to be able to prevent tumor growth in vivo by comparing the effects of LGMN overexpression TAMs and LGMN knockdown TAMs.The expression of angiogenic marker CD31 was significantly inhibited by immunohistochemistry (Xu et al., 2022), and the expression of malignant growth marker Ki67 was down-regulated in TAM-related tumors inhibited by LGMN, suggesting that LGMN-inhibited TAM can reduce tumor growth and angiogenesis in vivo. Here, PECAM1 is linked to neoplasm.